Acquisitions and Other Strategic Transactions - Narrative (Details) € in Millions													3 Months Ended	12 Months Ended			24 Months Ended
	Nov. 06, 2020 USD ($)	Oct. 11, 2019 USD ($) shares	Aug. 01, 2019 USD ($)	Jun. 14, 2019 USD ($)	Mar. 28, 2019 USD ($)	Dec. 14, 2018 USD ($)	Nov. 13, 2018 USD ($)	Jul. 31, 2018 USD ($) shares	May 23, 2018 USD ($)	May 18, 2018 USD ($)	Apr. 06, 2018 USD ($)	Feb. 14, 2018 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($) shares	Dec. 31, 2020 EUR (€)
Business Acquisition [Line Items]
Contingent liability													$ 48,088,000	$ 36,917,000	$ 48,088,000
Payments to acquire intangible assets														3,288,000	3,324,000	$ 3,012,000
Impairment charges														$ 36,504,000	23,750,000	657,000
QX Medical, LLC
Business Acquisition [Line Items]
Payments to acquire intangible assets										$ 750,000
NinePoint Medical, Inc.
Business Acquisition [Line Items]
Loan from acquisition											$ 10,500,000
Interest rate on loan											9.00%
Total purchase price											$ 10,000,000
Option to purchase outstanding equity, up to											100.00%
Net sales related to acquisition															2,900,000	3,000,000.0
Impairment charges													20,500,000		20,500,000
Write off of accrued interest													$ (1,600,000)		(1,600,000)
Distribution agreements | QX Medical, LLC
Business Acquisition [Line Items]
Weighted average useful life										10 years
Fluidx
Business Acquisition [Line Items]
Ownership percentage														11.60%				11.60%
Payments to acquire shares					$ 2,000,000
Cagent Vascular, LLC
Business Acquisition [Line Items]
Ownership percentage														19.50%				19.50%
Payments to acquire shares								$ 2,200,000									$ 3,000,000.0
Preferred limited liability company units (in units) | shares								1,786,000									3,000,000
Fusion Medical, Inc.
Business Acquisition [Line Items]
Ownership percentage														19.50%				19.50%
KA Medical
Business Acquisition [Line Items]
Purchase consideration, upfront payment	$ 10,400,000
Purchase consideration, note payable	$ 4,000,000
Term of note payable	12 months
KA Medical | Developed technology
Business Acquisition [Line Items]
Weighted average useful life	17 years
Selio
Business Acquisition [Line Items]
Ownership percentage		19.50%
Equity method investment		$ 2,600,000
Loan from acquisition														$ 250,000
Interest rate on loan														5.00%				5.00%
Selio | Maximum
Business Acquisition [Line Items]
Loan commitment from acquisition | €																		€ 2
Selio | Ordinary shares
Business Acquisition [Line Items]
Shares acquired (in shares) | shares		3,900
Term of option to purchase equity		45 days
Selio | C Ordinary shares
Business Acquisition [Line Items]
Shares acquired (in shares) | shares		1,365
Fibrovein Holdings Limited
Business Acquisition [Line Items]
Purchase consideration, upfront payment			$ 13,700,000
Weighted average useful life			12 years
Contingent liability			$ 934,000
Fibrovein Holdings Limited | Developed technology
Business Acquisition [Line Items]
Weighted average useful life			12 years
Fibrovein Holdings Limited | STD Pharmaceutical Products Limited
Business Acquisition [Line Items]
Ownership percentage			100.00%
Brightwater
Business Acquisition [Line Items]
Purchase consideration, upfront payment				$ 35,000,000
Weighted average useful life				12 years 10 months 24 days
Brightwater | Developed technology
Business Acquisition [Line Items]
Weighted average useful life				13 years
Brightwater | Trademarks
Business Acquisition [Line Items]
Weighted average useful life				5 years
Brightwater | Customer Lists
Business Acquisition [Line Items]
Weighted average useful life				1 year
Brightwater | Maximum | Achievement of CE Certification
Business Acquisition [Line Items]
Earn-out payments				$ 5,000,000
Brightwater | Maximum | Achievement of Sales Milestones
Business Acquisition [Line Items]
Earn-out payments				$ 10,000,000
Vascular Insights
Business Acquisition [Line Items]
Purchase consideration, upfront payment						$ 40,000,000
Weighted average useful life						11 years 9 months 18 days
Contingent liability						$ 20,000,000
Net sales related to acquisition														$ 5,500,000	7,500,000
Vascular Insights | Developed technology
Business Acquisition [Line Items]
Weighted average useful life						12 years
Vascular Insights | Trademarks
Business Acquisition [Line Items]
Weighted average useful life						9 years
Vascular Insights | Customer Lists
Business Acquisition [Line Items]
Weighted average useful life						8 years
Cianna Medical
Business Acquisition [Line Items]
Purchase consideration, upfront payment							$ 135,000,000
Weighted average useful life							10 years 8 months 12 days
Working capital adjustment							$ 1,200,000
Net sales related to acquisition														45,300,000	49,500,000	6,300,000
Acquisition-related costs																3,500,000
Cianna Medical | Achievement of Supply Chain and Scalability Metrics
Business Acquisition [Line Items]
Earn-out payments							$ 15,000,000
Cianna Medical | Developed technology
Business Acquisition [Line Items]
Weighted average useful life							11 years
Cianna Medical | Trademarks
Business Acquisition [Line Items]
Weighted average useful life							10 years
Cianna Medical | Customer Lists
Business Acquisition [Line Items]
Weighted average useful life							8 years
Cianna Medical | Maximum | Achievement of Sales Milestones
Business Acquisition [Line Items]
Earn-out payments							$ 50,000,000
DirectACCESS Medical, LLC
Business Acquisition [Line Items]
Weighted average useful life									9 years 10 months 24 days
Total purchase price									$ 7,300,000
DirectACCESS Medical, LLC | Developed technology
Business Acquisition [Line Items]
Weighted average useful life									10 years
DirectACCESS Medical, LLC | Trademarks
Business Acquisition [Line Items]
Weighted average useful life									10 years
DirectACCESS Medical, LLC | Customer Lists
Business Acquisition [Line Items]
Weighted average useful life									5 years
Becton, Dickinson and Company
Business Acquisition [Line Items]
Weighted average useful life												8 years
Contingent liability												$ 1,600,000
Total purchase price												$ 100,300,000
Net sales related to acquisition														$ 42,600,000	$ 46,800,000	42,100,000
Acquisition-related costs																$ 1,800,000
Becton, Dickinson and Company | Developed technology
Business Acquisition [Line Items]
Weighted average useful life												8 years
Becton, Dickinson and Company | Trademarks
Business Acquisition [Line Items]
Weighted average useful life												9 years
Becton, Dickinson and Company | Customer Lists
Business Acquisition [Line Items]
Weighted average useful life												7 years